Abstract 116P
Background
Lung adenocarcinoma (LUAD) is the most prevalent subtype of non-small cell lung cancer. The prognostic role of Fibrous sheath interacting protein 1 (FSIP1) in LUAD remains unclear. Thus, this study aims to identify and validate the prognostic value of FSIP1 in LUAD and explore its molecular functions.
Methods
Single-cell RNA sequencing (scRNA-seq) data of LUAD patients were collected from Gene Expression Omnibus (GEO) database, the major cell types were identified based on known markers. Additionally, the expression of FSIP1 was detected in 180 LUAD samples, Kaplan-Meier (KM) analysis of high- and low-expression patients was conducted. Univariate and multivariate Cox regression analyses were utilized to assess the prognostic ability of FSIP1. Then, FSIP1-silenced human LUAD cell lines were constructed, and the functions of FSIP1 were explored. Finally, immune infiltration analysis was performed in LUAD patients.
Results
In this study, we identified LUAD FSIP1+ cancer cells by using scRNA-seq data from GEO database. Additionally, we investigated the protein level and prognostic value of FSIP1 in 98 LUAD patients using Tissue Microarray. Compared with the adjacent, FSIP1 was higher expressed in LUAD tissues. KM analysis revealed that the 5-year OS rate to be 30% to 59% (FSIP1High vs FSIP1Low) in Tissue Microarray. Univariate and multivariate COX regression showed that FSIP1 should be an independent factor in poor prognosis. The receiver operating characteristic curve (ROC) and time-ROC curve both indicated that FSIP1 had a good performance in prognostic model. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that FSIP1 was associated with migration. Migration assay and Western blotting showed that FSIP1 influenced cell migration and PI3K/AKT pathway. FSIP1 could influence the immune cell infiltration in lung adenocarcinoma patients.
Conclusions
This study verified that FSIP1 could serve as a valuable prognostic biomarker in LUAD and analyzed its impact on the disease and its association with the immune infiltration. The findings of this research provide valuable insights into the understanding of LUAD and could potentially lead to the development of new treatment strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Efficacy of immunotherapy in gastro-intestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype
Presenter: Emily Alouani
Session: Poster session 08
144P - Analysis of a novel predictive marker of immune checkpoint response in head and neck cancer, calculated from histopathological slides through inferred transcriptomics
Presenter: Johnathan Arnon
Session: Poster session 08
145P - Predicting the efficacy of immunotherapy in non-small cell lung cancer using machine learning based on simple clinical characteristics and biochemical indexes
Presenter: Lei Cheng
Session: Poster session 08
146P - Biomarkers and intrinsic/acquired resistance mechanisms for atezolizumab plus chemoradiotherapy in MSS locally advanced rectal cancer: An exploratory analysis of a single center, phase II study
Presenter: Wentao Tang
Session: Poster session 08
147P - Comparison of immune-checkpoint inhibitor therapy predictive marker tests microsatellite instability (MSI) and mismatch-repair deficiency (dMMR)
Presenter: Maja Nádorvári
Session: Poster session 08
148P - Clinical significance of CD4+ T cell subsets in peripheral blood for anti-PD-1/PD-L1 therapy
Presenter: Yoshimichi Haruna
Session: Poster session 08
149P - Evaluation of HLA genotype as predictive biomarker for immunological and clinical responses upon vaccination with PolyPEPI1018 cancer vaccine against colorectal cancer
Presenter: Joleen Hubbard
Session: Poster session 08
150P - Phase I/IIa trial of CD200R1 inhibitor 23ME-00610: Exploratory analyses of tissue-based and genetic biomarkers
Presenter: Albiruni Ryan Abdul Razak
Session: Poster session 08
151P - Enhanced pharmacodynamic effects upon combination of cibisatamab and FAP-4-1BBL in 3L+ mMSS CRC patients
Presenter: Ignacio Melero
Session: Poster session 08
152P - Exploratory biomarker analysis of phase III ASTRUM-004 study: Serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer
Presenter: Caicun Zhou
Session: Poster session 08